Ultragenyx Pharmaceutical (RARE) Receivables (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Receivables data on file, last reported at $122.0 million in Q1 2026.

• Receivables for Q1 2026 came in at $122.0 million, up 182.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.0 million (up 182.41% YoY), and the FY2025 annual result was $159.0 million, up 82.76% from the prior year.
• Receivables slipped to $122.0 million in Q1 2026 per RARE's latest filing, from $159.0 million in the prior quarter.
• Over five years, Receivables peaked at $159.0 million in Q4 2025 and troughed at $3.8 million in Q3 2025.
• A 5-year average of $61.2 million and a median of $47.1 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2025: Receivables surged 332.95% in 2023, then sank 93.41% in 2025.
• A 5-year view of Receivables shows it stood at $33.9 million in 2022, then advanced by 18.88% to $40.3 million in 2023, then jumped by 115.88% to $87.0 million in 2024, then jumped by 82.76% to $159.0 million in 2025, then dropped by 23.27% to $122.0 million in 2026.
• Business Quant data shows RARE's Receivables at $122.0 million in Q1 2026, $159.0 million in Q4 2025, and $3.8 million in Q3 2025.